Life Sciences Genomics Sequencing Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Genomics Sequencing Platforms
1.1 - About Life Sciences Genomics Sequencing Platforms sector
Companies in the Life Sciences Genomics Sequencing Platforms category build hardware, consumables, assays, and software that capture and analyze DNA and RNA at scale. Their systems power discovery and clinical workflows by delivering high-throughput sequencing, robust variant detection, and reproducible results across research and diagnostics. Buyers rely on these platforms for faster data generation, lower cost per sample, and actionable genomic insights.
Offerings span short- and long-read next-generation sequencing instruments, single-cell RNA and immune profiling workflows, genotyping arrays and targeted panels, and whole-exome plus transcriptome assays for therapy selection. Vendors provide library prep reagents, barcoding chemistries, on-instrument methylation calling, and ultra-sensitive protein detection via digital ELISA, complemented by metabolomics. Integrated bioinformatics pipelines, LIMS, and cloud analysis deliver quality control, variant calling, and interactive reporting for scalable multi-omics studies.
Primary customers include biopharma R&D teams, clinical diagnostics laboratories, and academic genomics cores. With these platforms, organizations accelerate biomarker discovery, enable precision oncology therapy selection, increase throughput for population-scale studies, and reduce cost per genome or assay. They also improve data quality and reproducibility, streamline sample-to-report workflows, and support compliance-ready documentation to translate research into clinically actionable results.
2. Buyers in the Life Sciences Genomics Sequencing Platforms sector
2.1 Top strategic acquirers of Life Sciences Genomics Sequencing Platforms companies
Illumina
HQ: United States
Website
- Description: Provider of next-generation life-science tools and integrated systems that analyze genetic variation and biological function, offering proprietary sequencing, genotyping and gene-expression products and services that deliver high performance, throughput, cost effectiveness and flexibility for genomic research, pharmaceutical, clinical and biotechnology customers.
- Key Products:
- Sequencing Platforms: Proprietary next-generation sequencing systems deliver high performance, high throughput and cost-effective DNA analysis, enabling billions of genetic tests for research and clinical applications
- Genotyping Solutions: Comprehensive genotyping products provide large-scale analysis of genetic variation across genomes, supporting pharmacogenomics, academic and clinical studies with flexible, high-throughput arrays and assays
- Gene Expression Analysis Products: Integrated tools quantify gene expression to elucidate biological function and disease mechanisms, offering scalable workflows for researchers to correlate expression data with genetic variation
- Integrated Life-Science Systems & Services: End-to-end systems combining sequencing, genotyping and expression technologies with supporting services give genomic centers and biotech firms flexible, high-quality platforms for large-scale studies.
- Rationale: Provider of NovaSeq X high-throughput sequencers, Infinium genome-wide genotyping arrays, and DRAGEN accelerated secondary analysis for variant detection.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Genomics Sequencing Platforms sector
M&A buyer group 1: Nucleic Acid Sequencing
5 companies
View group →
Description: Companies in the Life Sciences Nucleic Acid Sequencing Platforms category design and supply instruments, chemistries, automation, and analytics to sequence DNA and RNA at scale. They enable high-throughput genomic analysis for research, translational medicine, and diagnostics, reducing turnaround times and cost per sample while improving accuracy and reproducibility. Strategic buyers in this space typically offer integrated hardware, reagents, and software to support end‑to‑end sequencing workflows.
Neogen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of food safety and quality assurance solutions for the pet-food sector, offering mycotoxin, pathogen, sanitation and allergen tests, environmental monitoring with microbiome analysis and analytics, plus verification tools, biosecurity, vector control and companion animal health products.
- Key Products:
- Environmental Monitoring Solutions: Provides Salmonella and ATP tests, analytic software, metagenomic microbiome analysis and biosecurity tools to strengthen facility-wide safety programs and enable rapid, data-driven contamination control
- Mycotoxin Testing Kits: Easy-to-use, fast and accurate kits that detect multiple mycotoxins, integrate seamlessly into safety programs and are supported by reference materials, proficiency testing and 24/7 assistance
- Vector Control Solutions: Broad portfolio of rodenticides and insecticides that follow a four-step prevention, identification, execution and monitoring program to eliminate disease-carrying pests in operations
- Companion Animal Health Products: Includes PanaKare Plus supplements for exocrine pancreatic insufficiency and RenaKare potassium supplementation, supporting specific nutritional needs of cats and dogs.
🔒
🔒
🔒
View all 5 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Genomics Sequencing Platforms sector
3.1 - Buyout funds in the Life Sciences Genomics Sequencing Platforms sector
2.2 - Strategic buyer groups for Life Sciences Genomics Sequencing Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Genomics Sequencing Platforms companies
4.2 - Public trading comparable groups for Life Sciences Genomics Sequencing Platforms sector
Valuation benchmark group 1: Clinical and Molecular Diagnostics Companies
8 companies
View group →
Description: Companies in this public trading comparables group provide clinical laboratory and molecular diagnostics, including lab-based testing, oncology assays, and point-of-care devices. Revenue is driven by fee-for-service testing, test panels, device sales, and managed lab services. They are grouped together as valuation benchmarks due to shared regulatory and reimbursement dynamics, similar clinical workflows, common demand drivers (screening and monitoring), and overlapping payer and provider customer bases.
Labcorp
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive clinical laboratory and drug development services, harnessing science for human good with a wide range of diagnostic tests, specialty testing services, and research support globally.
- Key Products:
- Diagnostic Testing: Wide range of diagnostic tests for various conditions
- Specialty Testing: Advanced gene-based and esoteric testing
- Drug Development Services: Comprehensive services for drug development and clinical trials
- Health Screenings: Wellness, pediatric, COVID-19 antibody testing
- Labcorp OnDemand: At-home test kits and monitoring solutions
🔒
🔒
🔒
View all 8 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →